B
Bull
Bull · 25%CV
$5.79
Szenariopreis
$5.930
-0.127 (-2.15%)Zum Schluss
Loading chart…
- High
- 6.284
- Open
- 6.130
- VWAP
- 6.05
- Vol
- 83.05K
- Mkt Cap
- —
- Low
- 5.930
- Amount
- 502.27K
- EV/EBITDA, TTM
- -7.28
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule.
AI analysis of CapsoVision Inc (CV)
buyCapsoVision Inc is a good buy right now, trading at $5.93 with a forward P/E of 0 and a gross margin of 51.36%. The recent 10% revenue growth in Q2 2026 and the positive analyst ratings suggest strong potential for recovery and growth. However, the main risk is the net income loss of $7.48 million in Q2 2026, which indicates ongoing financial challenges.
Bewertungskennzahlen
The current forward P/E ratio for CapsoVision Inc (CV) is 0.00, compared to its 5-year average forward P/E of -10.86.
Alphio AI Price Scenarios for CV
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Event-Zeitleiste
News
9.508-14Yahoo FinanceCapsoVision Reports 10% Revenue Growth in Q2 2026
9.508-04NASDAQ.COMCRISPR Therapeutics Reports Narrowed Loss in Q2 2026
5.008-04NASDAQ.COMCapsoVision Launches AI Highlights for Capsule Endoscopy Studies
5.008-03GlobenewswireCapsoVision Launches AI Highlights for Capsule Endoscopy
5.008-03NewsfilterCapsoVision Launches AI Highlights for Capsule Endoscopy
CV FAQ — answered by Alphio AI
CapsoVision, Inc. is a global medical device innovator which specializes in diagnostic imaging of the gastrointestinal system. Its flagship product, CapsoCam Plus, is a small bowel capsule endoscope that uses a novel 360 panoramic lateral view to overcome the limitations of end-facing cameras and provide a more comprehensive imaging solution, while its wire-free design provides unparalleled comfort and convenience to patients. Its CapsoCloud is a next generation, cloud-based software application that makes clinical data management convenient and secure. Its capsule collection kit is a sanitary, single-use kit provided to patients for the collection, storage and transportation of the CapsoCam Plus capsule. It operates in the Healthcare sector.
CapsoVision Inc is a good buy right now, trading at $5.93 with a forward P/E of 0 and a gross margin of 51.36%. The recent 10% revenue growth in Q2 2026 and the positive analyst ratings suggest strong potential for recovery and growth. However, the main risk is the net income loss of $7.48 million in Q2 2026, which indicates ongoing financial challenges.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.